We are live on
!
Find out more
VCM
Versant Capital Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
34.21%
This Fund
S&P 500
This Quarter
Est. Return
+13.52%
1 Year Est. Return
+34.21%
3 Year Est. Return
+82.39%
5 Year Est. Return
+89.4%
10 Year Est. Return
+245.39%
AUM
$1.12B
AUM Growth
+$101M
(+10%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
1.71%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
2,873
New
96
Increased
1,181
Reduced
859
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DXUV
Dimensional US Vector Equity ETF
DXUV
|
+$8.37M |
| 2 |
Dimensional Emerging Markets Core Equity 2 ETF
DFEM
|
+$7.66M |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$6.75M |
| 4 |
DXIV
Dimensional International Vector Equity ETF
DXIV
|
+$4.35M |
| 5 |
Dimensional Emerging Markets Value ETF
DFEV
|
+$2.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 3-7 Year Treasury Bond ETF
IEI
|
+$2.11M |
| 2 |
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
|
+$2.02M |
| 3 |
Vanguard Total Stock Market ETF
VTI
|
+$1.88M |
| 4 |
CoreCivic
CXW
|
+$1.84M |
| 5 |
Apple
AAPL
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.06% |
| 2 | Financials | 7.05% |
| 3 | Industrials | 6.04% |
| 4 | Consumer Discretionary | 4.74% |
| 5 | Healthcare | 4.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Eastern Bankshares
EBC
$5.25B
| $30.8K | ﹤0.01% |
1,385
| – | – |
|
1702
Yelp
YELP
$1.38B
| $30.8K | ﹤0.01% |
1,256
-2,370
| -65% | -$59K |
|
1703
Malibu Boats
MBUU
$544M
| $30.7K | ﹤0.01% |
1,119
-326
| -23% | -$8.67K |
|
1704
Invesco FTSE RAFI US 1000 ETF
PRF
$9.73B
| $30.7K | ﹤0.01% |
+568
| New | +$29.6K |
|
1705
AnaptysBio
ANAB
$1.6B
| $30.6K | ﹤0.01% |
454
| – | – |
|
1706
Weis Markets
WMK
$1.82B
| $30.6K | ﹤0.01% |
391
+347
| +789% | +$25.5K |
|
1707
Capitol Federal Financial
CFFN
$1.08B
| $30.6K | ﹤0.01% |
3,594
| – | – |
|
|
UMH
1708
UMH Properties
UMH
$1.32B
| $30.6K | ﹤0.01% |
2,020
-227
| -10% | -$3.47K |
|
1709
Invesco Taxable Municipal Bond ETF
BAB
$1.02B
| $30.5K | ﹤0.01% |
1,135
+11
| +1% | +$295 |
|
1710
COPT Defense Properties
CDP
$4.31B
| $30.4K | ﹤0.01% |
835
| – | – |
|
1711
Utah Medical Products
UTMD
$214M
| $30.4K | ﹤0.01% |
440
-6
| -1% | -$399 |
|
1712
Vanguard Mid-Cap ETF
VO
$106B
| $30.3K | ﹤0.01% |
376
| – | – |
|
1713
RXO
RXO
$4.23B
| $30.2K | ﹤0.01% |
1,095
| – | – |
|
1714
Gorman-Rupp
GRC
$2.16B
| $30.2K | ﹤0.01% |
329
| – | – |
|
|
ABVX
1715
Abivax
ABVX
$11B
| $30.1K | ﹤0.01% |
+226
| New | +$25.6K |
|
1716
Lumen
LUMN
$6.53B
| $30.1K | ﹤0.01% |
3,920
+1,860
| +90% | +$16.3K |
|
1717
PIMCO Corporate & Income Opportunity Fund
PTY
$2.48B
| $30.1K | ﹤0.01% |
2,500
| – | – |
|
1718
YieldMax TSLA Option Income Strategy ETF
TSLY
$613M
| $30K | ﹤0.01% |
1,052
+286
| +37% | +$8.37K |
|
1719
G-III Apparel Group
GIII
$1.47B
| $29.9K | ﹤0.01% |
886
| – | – |
|
1720
J&J Snack Foods
JJSF
$1.43B
| $29.8K | ﹤0.01% |
406
-275
| -40% | -$21.4K |
|
1721
Twist Bioscience
TWST
$5.62B
| $29.7K | ﹤0.01% |
289
+2
| +0.7% | +$130 |
|
1722
ARKO Corp
ARKO
$890M
| $29.7K | ﹤0.01% |
3,702
| – | – |
|
1723
Merchants Bancorp
MBIN
$2.19B
| $29.7K | ﹤0.01% |
594
| – | – |
|
1724
Sprouts Farmers Market
SFM
$7.04B
| $29.6K | ﹤0.01% |
350
+51
| +17% | +$4.12K |
|
1725
Varex Imaging
VREX
$460M
| $29.5K | ﹤0.01% |
2,832
-283
| -9% | -$3.05K |
|
Similar funds
FLAM
AIM
MTCM
CNC
NOSC
RIM
ACG
C
Versant Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Versant Capital Management held 2,873 positions worth $1.12B, up 10% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Versant Capital Management's Q2 2026 filing shows 96 new, 1,181 increased, 859 reduced and 128 closed positions. Its largest new stake was AstraZeneca: 7,263 shares worth $1.36M. The largest sale was iShares 3-7 Year Treasury Bond ETF, an estimated $2.11M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Industrials.
- Versant Capital Management's largest Q2 2026 buy was AstraZeneca: 7,263 shares worth $1.36M.
- Versant Capital Management added most to Dimensional US Vector Equity ETF in Q2 2026, an estimated $8.37M increase.
- Versant Capital Management's biggest Q2 2026 reduction was iShares 3-7 Year Treasury Bond ETF, cutting an estimated $2.11M.
- Versant Capital Management fully exited iShares 5-10 Year Investment Grade Corporate Bond ETF in Q2 2026, selling an estimated $2.02M.
- Versant Capital Management's ten largest holdings make up 32% of its $1.12B portfolio in Q2 2026.
- Versant Capital Management opened 96 new positions and closed 128 in Q2 2026.
- Versant Capital Management's portfolio value rose 10% quarter-over-quarter to $1.12B.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.